Working with affinity tools that offer the highest batch consistency is critical for the development of robust assays and reliable data. Optimer binders deliver the best batch-to-batch consistency for…
As SARS-CoV-2 continues to mutate we demonstrate the performance of
Why we do this. What the benefit is for you. Aptamers are increasingly being used across the life sciences in research, diagnostics and therapeutics. We have years of experience in…
The selective disruption of protein-protein interactions holds potential for new drug discovery strategies. Dr Katherine Bridge is a Research Fellow at the University of York investigating the role of…
Rapid and reversible aptamer binding is helping to build new in vivo biosensors that will change the way we diagnose and treat disease. Dr Netz Arroyo is an Assistant Professor…
The reproducible performance and wide target range of aptamers are enabling researchers of all levels in the pursuit of better diagnostics. Dr Mark Platt at…
Monitoring antibiotic concentrations is challenging with traditional affinity reagents, especially for small molecule targets. This limitation has restricted research and diagnostic potential in the field. Optimers can be…
Researchers at the National Cancer Institute (Centro di Referimento Oncologico IRCCS), Aviano, Italy, have published a new paper in Analytical and Bioanalytical Chemistry. Using aptamers from Aptamer…
Presented at SLAS 2021 by collaborators at Boston University showing Aptamer Group’s COVID-19 Optimers used in the high content imager platform, MuviCyte, to help further our understanding of viruses…
In the recently published paper in Talenta from Dr Mark Platt and the team at Loughborough University, they demonstrate a novel approach for aptamer biosensors to detect…
